Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy Sells 20,000 Shares of Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 20,000 shares of Alpha Tau Medical stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $11.00, for a total transaction of $220,000.00. Following the completion of the transaction, the chief financial officer directly owned 110,180 shares in the company, valued at $1,211,980. The trade was a 15.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total transaction of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Trading Up 11.1%

NASDAQ DRTS opened at $11.17 on Friday. The firm’s fifty day moving average is $9.33 and its two-hundred day moving average is $7.59. Alpha Tau Medical Ltd. has a one year low of $2.87 and a one year high of $11.62. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The firm has a market cap of $1.01 billion, a PE ratio of -16.67 and a beta of 1.19.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). Analysts expect that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current year.

Institutional Trading of Alpha Tau Medical

Large investors have recently made changes to their positions in the stock. Trifecta Capital Advisors LLC purchased a new stake in shares of Alpha Tau Medical in the fourth quarter valued at $48,000. Envestnet Asset Management Inc. acquired a new stake in Alpha Tau Medical in the 3rd quarter worth about $62,000. Bank of America Corp DE boosted its stake in Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after buying an additional 21,677 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Alpha Tau Medical by 291.7% in the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after buying an additional 17,500 shares during the period. Finally, Principal Financial Group Inc. acquired a new position in shares of Alpha Tau Medical during the 1st quarter valued at about $132,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on DRTS shares. Barclays boosted their target price on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. LADENBURG THALM/SH SH increased their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Alpha Tau Medical in a report on Tuesday, June 2nd. Finally, Citigroup boosted their target price on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $12.60.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.